Key Takeaways PAHC's Animal Health sales surged 53% in Q4, boosted by Zoetis products and strong global demand. PAHC's Mineral Nutrition and Performance Products sales rose on higher demand and improved selling prices. PAHC ended fiscal 2025 with $77M cash and just$16M in short-term debt, showing strong solvency. Phibro Animal Health Corporation’s (PAHC) focus on advancing its Animal Health business drove growth in the fourth quarter of fiscal 2025. The company’s recovery within Mineral Nutrition and Perf ...